Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer’s disease via data fusion and machine learning
Accurately predicting which individuals with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) can improve patient care. This study examines the role of quantitative MRI (qMRI), cognitive evaluations, apolipoprotein [Formula: see text]4 (APOE [Formula: see text]4), and cerebrospinal fluid (CSF) biomarkers in Cox survival models to predict progression from MCI to AD. Data from 564 participants in the ADNI study, who transitioned from MCI to AD, were analyzed. The data set included 330 features encompassing qMRI, cognitive assessments, CSF biomarkers, and APOE [Formula: see text]4 status. Advanced machine learning (ML) methods were applied to evaluate the importance of these data sources, select relevant features, and develop interpretable Cox survival models within a cross-validation framework. The top optimized model achieved a sensitivity of 0.69, 95% CI [0.63, 0.76], and a specificity of 0.87, 95% CI [0.83, 0.90], and used all data sources. The results demonstrated that combining qMRI features with cognitive assessments, CSF biomarkers, and APOE [Formula: see text]4 status, analyzed using the BSWiMS model, resulted in a substantial improvement in the ability to predict progression from MCI to AD, achieving 81% precision and 87% specificity. These results exceed those obtained with other models evaluated. Finally, biomarker analysis showed that cognitive scores are the most relevant features to predict conversion, followed by CSF and qMRI biomarkers. These findings highlight the value of integrating multiple data sources in highly interpretable Cox survival models for the early identification of individuals at risk for AD.
Authors
- Diana Sofia Rosales-Gurmendi
- Emmanuel Martínez-Ledesma (ORCID: https://orcid.org/0000-0003-1191-7917)
- Antonio Martínez‐Torteya (ORCID: https://orcid.org/0000-0002-7637-4637)
- Victor Trevino
- Gerardo Alejandro Fumagal-González (ORCID: https://orcid.org/0009-0008-2041-8056)
- Faiola Rosales-Gurmendi
- Joshua Farber
- Jorge Orozco
- Jose Tamez-Peña
- for the Alzheimer’s Disease Neuroimaging Initiative
Institutions
- Universidad Peruana Cayetano Heredia (PE)
- QED Technologies (United States) (US)
- Universidad Ateneo de Monterrey (MX)
- University of Monterrey (MX)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-04-30
- DOI
- https://doi.org/10.1371/journal.pone.0321671
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Secretaría de Educación Superior, Ciencia, Tecnología e Innovación
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research